title: [Effect and role of teriparatide in the treatment of osteoporosis].
abstract: Teriparatide, a treatment formula of parathyroid hormone (PTH) , is a powerful anabolic agent on bone, improving its mass, geometry and microarchitecture. It can decrease the occurrence of fracture in the subjects with increased fracture risks. Teriparatide can provide good protection against fracture using as monotherapy, and possibly as combination with an antiresorptive agent such as zoledronate. Teriparatide should be considered in patients with osteoporosis who sustained the reduction of BMD or fracture on established bisphosphonates or SERMs. Treatment period of teriparatide is 1.5-2 years and consecutive use of antiresorptive agents is greatly recommended to secure long-term protection against fracture after teriparatide treatment.
authors.affiliation: Department of Orthopedics, University of Occupational and Environmental Health, Japan.
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D019379:Teriparatide / Q000008:administration & dosage*; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide; D013739:Testosterone; C016131:testosterone 17 beta-cypionate